AVENIO Tumor Tissue Analysis Kits

Overview

AVENIO Tumor Tissue Analysis Kits are a portfolio of three NGS assays that provide a simpler, optimized workflow for the detection of all four mutation classes from the DNA of formalin-fixed paraffin-embedded (FFPE) tissue samples.

The three AVENIO tissue assays contain matched panel content with the three corresponding AVENIO ctDNA liquid biopsy assays.

Overview

Features and Benefits of AVENIO Tumor Tissue Analysis Kits

Exactly-matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis
All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with AVENIO tumor tissue assays
Flexibility to switch between tissue and plasma to support a variety of research applications
A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports

Exceptional Performance

End-to-end workflow from extraction to analysis and reporting in five days

AVENIO Tumor Tissue Targeted Kit

The AVENIO Tumor Tissue Targeted Kit is a 17 gene (81kb) pan-cancer assay that contains guideline-aligned biomarkers, including those identified by the U.S. National Comprehensive Cancer Network (NCCN).

Learn more

AVENIO Tumor Tissue Expanded Kit

The AVENIO Tumor Tissue Expanded Kit is a 77 gene (192kb) pan-cancer assay that contains 17 NCCN guideline-aligned genes, plus 60 emerging biomarkers investigated in clinical research for expanded profiling of solid tumors.

Learn more

AVENIO Tumor Tissue Surveillance Kit

The AVENIO Tumor Tissue Surveillance Kit is a 197 gene (198kb) pan-cancer assay that contains 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 180 genes; optimized for longitudinal monitoring of tumor burden and detection of minimal residual disease in lung cancer and colorectal cancer.

Learn more

References

Data on file.
National Comprehensive Cancer Network. October 15, 2016.

Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. NextSeq is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.